Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Real-world Experience of Anti-PD-1 Immunotherapy Plus Chemotherapy as First-line Treatment for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China(REACTION Trial).
1 other identifier
observational
1,197
1 country
23
Brief Summary
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2021
Longer than P75 for all trials
23 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 31, 2021
CompletedStudy Start
First participant enrolled
October 31, 2021
CompletedFirst Posted
Study publicly available on registry
December 3, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedFebruary 5, 2026
October 1, 2024
1.9 years
October 31, 2021
February 4, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
OS from start of 1st line treatment in metastatic ESCC
Median OS and OS rate at 12 months, 18 months and 24 months will be analysed based on Kaplan-Meier method and presented along with its 95% confidence interval.
2 years
Secondary Outcomes (2)
PFS from start of 1st line treatment in metastatic ESCC
18 months
the role of radiotherapy for patients treated with 1st immunotherapy.
2 years
Study Arms (1)
ESCC patients treated with anti-PD-1 immunotherapy as 1st line treatment.
Interventions
used as 1st line treatment for metastatic ESCC.
Eligibility Criteria
More than 600 patients
You may qualify if:
- Age \> 18, had an Eastern Cooperative Oncology Group performance status score of 0-3; Patients had unresectable or recurrent disease that precluded esophagectomy or definitive chemoradiation, or distant metastatic disease; Patients had received no previous systemic therapy (patients who had progressed ≥6 months after \[neo\]adjuvant therapy or definitive chemoradiation were eligible); Patients accepted at least one cycle of anti-PD-1 immunotherapy as 1st line treatment, combined chemotherapy was allowed.
- Patients who provided informed consent by appropriate methods. In dead case, optout will be applicable.
You may not qualify if:
- Patients who are prior exposure to immune-mediated therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fudan Universitylead
Study Sites (23)
The 2nd affiliated hospital of Bengbu medical University
Bengbu, Anhui, China
The 2nd people's hospital of Anhui province
Hefei, Anhui, China
Fujian Cancer Hospital & Fujian Medical University Cancer Hospital
Fuzhou, Fujian, China
The 1st affiliated hospital of Xiamen University
Xiamen, Fujian, China
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center
Shenzhen, Guangdong, China
The 4th affiliated hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Anyang cancer hospital
Anyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Wuhan University Zhongnan hospital
Wuhan, Hubei, China
Zhongnan University Xiangya Hospital
Changsha, Hunan, China
Huai'an first hospital
Huai'an, Jiangsu, China
Jiangsu cancer Hosipital
Nanjing, Jiangsu, China
Nantong cancer hospital
Nantong, Jiangsu, China
Yancheng the 3rd hospital
Yancheng, Jiangsu, China
The Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
The 1st affiliated hospital of Nanchang University
Nanchang, Jiangxi, China
The 2nd affiliated hospital of Nanchang University
Nanchang, Jiangxi, China
The First Affiliated Hospital of Air Force Medical University
Xi'an, Shaanxi, China
Fudan University Shanghai cancer center
Shanghai, Shanghai Municipality, 200032, China
Sichuan cancer hospital
Chengdu, Sichuan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
The 2nd affiliated hospital of Wenzhou medical university
Wenzhou, Zhejiang, China
Related Publications (1)
Liu Q, Chen J, Shen W, Ye J, Luo H, Zhang X, Liu W, Xu Y, Zhang Y, Liu A, Li X, Ge H, Wang Q, Luo H, Zhao L, Xie C, Lin Q, Xie C, Wang L, Zhao K. The role of thoracic radiotherapy in the setting of immunotherapy in polymetastatic esophageal squamous cell carcinoma: a multi-center cohort study. Ther Adv Med Oncol. 2026 Feb 12;18:17588359261419635. doi: 10.1177/17588359261419635. eCollection 2026.
PMID: 41696558DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lvhua Wang, M.D.
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- PRINCIPAL INVESTIGATOR
Kuaile Zhao, M.D.
Fudan University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
October 31, 2021
First Posted
December 3, 2021
Study Start
October 31, 2021
Primary Completion
September 30, 2023
Study Completion
December 31, 2025
Last Updated
February 5, 2026
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share